SecurityGLPG / Galapagos N.V. (36315X101)
Institutional Owners78
Institutional Shares21,122,650
Institutional Value$ 929,465,000 USD

Institutional Stock Ownership and Shareholders

Galapagos N.V. (NASDAQ:GLPG) has 78 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 21,122,650 shares. Largest shareholders include Gilead Sciences Inc, Van Herk Investments B.v., FMR LLC / Fidelity, Sands Capital Management, Llc, Federated Investors Inc /pa/, Orbimed Advisors Llc, BlackRock Inc., Farallon Capital Management Llc, Wellington Management Group LLP, and Baker Brothers Advisors LP.

Galapagos N.V. (NASDAQ:GLPG) ownership summary shows current positions in the company by institutions and funds, as well as latest changes in position size. Major shareholders can include individual investors, mutual funds, hedge funds, or institutions. The Schedule 13D indicates that the investor holds more than 5% of the company and intends to actively pursue a change in business strategy. Schedule 13G indicates a passive investment of over 5%. Green rows indicate new positions. Red rows indicate closed positions. Click the link icon to see the full transaction history.


File DateFormInvestor Opt Prev
Shares
Current
Shares
Change
(Percent)
Prev Value
($1000)
Current Value
($1000)
Change
(Percent)
2018-02-28 13F-HR/A-1 FEDERATED INVESTORS INC /PA/ 1,349,600 1,350,534 0.07 137,322 126,626 -7.79
2018-02-09 13F-HR CITADEL ADVISORS LLC 14,179 2,870 -79.76 1,443 269 -81.36
2018-02-14 13F-HR SANDS CAPITAL MANAGEMENT, LLC 2,036,016 1,998,311 -1.85 207,165 187,362 -9.56
2018-02-14 13F-HR HBK INVESTMENTS L P 12,491 2,987 -76.09 1,271 280 -77.97
2017-10-26 13F-HR Acrospire Investment Management LLC 7 0 -100.00 1 0 -100.00
2018-02-09 13F-HR Tower Research Capital LLC (TRC) 20 1,488 7,340.00 2 140 6,900.00
2018-02-12 13F-HR CITIGROUP INC 0 355 0 33
2018-02-09 13F-HR Employees Retirement System of Texas 54,000 54,000 0.00 5,495 5,063 -7.86
2018-03-07 13F-HR Private Capital Group, Llc 70 4
2018-02-14 13F-HR MORGAN STANLEY 64,274 84,133 30.90 6,539 7,888 20.63
2017-11-09 13F-HR Trexquant Investment LP 2,800 0 -100.00 214 0 -100.00
2017-11-13 13F-HR ASCEND CAPITAL, LLC 73,964 0 -100.00 5,661 0 -100.00
2018-02-14 13F-HR EVENTIDE ASSET MANAGEMENT, LLC 52,000 52,000 0.00 5,291 4,876 -7.84
2018-02-13 13F-HR Financial Gravity Companies, Inc. 880 104
2018-02-14 13F-HR FARALLON CAPITAL MANAGEMENT LLC 236,216 290,000 22.77 24,035 27,190 13.13
2018-02-08 13F-HR WELLS FARGO & COMPANY/MN 734 662 -9.81 75 62 -17.33
2018-02-12 13F-HR Quantbot Technologies LP 148 766 417.57 15 71 373.33
2018-02-02 13F-HR COMERICA BANK 2,730 2,730 0.00 265 312 17.74
2018-02-14 13F-HR UBS Group AG 1,150 1,597 38.87 117 150 28.21
2018-02-14 13F-HR Cubist Systematic Strategies, LLC 3,513 0 -100.00 357 0 -100.00
2018-01-12 13F-HR ATRIA INVESTMENTS LLC 2,933 3,609 23.05 298 338 13.42
2018-02-14 13F-HR MACQUARIE GROUP LTD 8,637 9,600 11.15 879 900 2.39
2018-02-14 13F-HR Atika Capital Management LLC 46,000 15,500 -66.30 4,683 1,453 -68.97
2018-02-14 13F-HR DEERFIELD MANAGEMENT CO 130,000 130,000 0.00 13,228 12,189 -7.85
2018-02-14 13F-HR DRIEHAUS CAPITAL MANAGEMENT LLC 5,988 0 -100.00 609 0 -100.00
2018-03-05 13F-HR/A-1 NORGES BANK 70,000 6,563
2018-02-09 13F-HR ARROWSTREET CAPITAL, LIMITED PARTNERSHIP 0 38,952 0 3,652
2018-02-14 13F-HR Baker Brothers Advisors LP 259,894 259,894 0.00 26,444 24,368 -7.85
2018-02-12 13F-HR Pacad Investment Ltd. 0 200 0 19
2017-11-14 13F-HR Cormorant Asset Management, LLC 300,000 0 -100.00 22,918 0 -100.00
2018-01-17 13F-HR Cutler Group LP Call 600 2,100 250.00 4 6 50.00
2017-11-14 13F-HR SPRINGBOK CAPITAL MANAGEMENT, LLC 468 0 -100.00 36 0 -100.00
2018-02-14 13F-HR MILLENNIUM MANAGEMENT LLC 0 45,404 0 4,257
2018-02-14 13F-HR ORBIMED ADVISORS LLC 523,790 486,990 -7.03 53,296 45,660 -14.33
2018-02-02 13F-HR Aperio Group, LLC 4,159 7,603 82.81 423 713 68.56
2017-11-06 13F-HR NEW YORK STATE COMMON RETIREMENT FUND 2,173 0 -100.00 166 0 -100.00
2018-02-14 13F-HR DAFNA Capital Management LLC 31,609 39,609 25.31 3,216 3,714 15.49
2018-02-14 13F-HR SUSQUEHANNA INTERNATIONAL GROUP, LLP 19,684 18,837 -4.30 2,003 1,766 -11.83
2018-02-14 13F-HR ROYAL BANK OF CANADA 50 81 62.00 5 8 60.00
2018-04-06 13F-HR Eqis Capital Management, Inc. 11,343 12,344 8.82 1,064 1,231 15.70
2018-02-13 13F-HR ALLIANCEBERNSTEIN L.P. 17,410 38,050 118.55 1,771 3,568 101.47
2017-11-13 13F-HR Hudson Bay Capital Management LP 20,000 0 -100.00 1,530 0 -100.00
2018-04-18 13F-HR/A-1 FNY Partners Fund LP 20,200 0 -100.00 1,893 0 -100.00
2018-02-14 13F-HR ProShare Advisors LLC 5,875 551
2018-02-13 13F-HR LANDSCAPE CAPITAL MANAGEMENT, L.L.C. 3,247 4,141 27.53 330 388 17.58
2017-11-14 13F-HR Weiss Multi-Strategy Advisers LLC 20,000 0 -100.00 1,530 0 -100.00
2018-01-17 13F-HR Cutler Group LP Put 3,300 900 -72.73 1 10 900.00
2017-11-01 13F-HR STEVENS CAPITAL MANAGEMENT LP 3,813 0 -100.00 292 0 -100.00
2018-02-14 13F-HR Dorsey Wright & Associates 48,357 66,187 36.87 4,944 6,205 25.51
2018-03-14 13F-HR/A-1 CREDIT SUISSE AG/ 32,084 95,195 196.71 3,264 8,926 173.47
2018-02-20 13F-HR ENVESTNET ASSET MANAGEMENT INC 1,742 2,315 32.89 177 217 22.60
2018-02-14 13F-HR Belpointe Asset Management Llc 2,762 2,651 -4.02 281 249 -11.39
2018-02-14 13F-HR GOLDMAN SACHS GROUP INC 121,136 116,616 -3.73 12,325 10,934 -11.29
2018-02-02 13F-HR US BANCORP \DE\ 3,842 2,501 -34.90 391 235 -39.90
2018-04-16 13F-HR PEREGRINE CAPITAL MANAGEMENT LLC 117,211 102,136 -12.86 10,990 10,189 -7.29
2018-02-09 13F-HR Dynamic Technology Lab Private Ltd 2,144 0 -100.00 218 0 -100.00
2018-01-17 13F-HR Cutler Group LP 600 500 -16.67 61 46 -24.59
2018-02-15 13F-HR Her Majesty the Queen in Right of the Province of Alberta as represented by Alberta Investment Management Corp 70,000 70,000 0.00 7,123 6,563 -7.86
2018-02-14 13F-HR Advisor Group, Inc. 2,829 3,492 23.44 288 327 13.54
2018-02-14 13F-HR GLG Partners LP 0 2,979 0 279
2018-02-08 13F-HR Advisory Services Network, LLC 499 47
2018-02-09 13F-HR BlackRock Inc. 150,600 346,802 130.28 15,323 32,516 112.20
2017-11-13 13F-HR Graticule Asia Macro Advisors LLC 41,818 0 -100.00 3,200 0 -100.00
2018-02-14 13F-HR Rock Springs Capital Management LP 214,000 185,000 -13.55 21,775 17,346 -20.34
2018-01-16 13F-HR NEXT Financial Group, Inc 3 0 -100.00 0 0
2018-04-13 13F-HR BANK OF MONTREAL /CAN/ 5,205 5,205 0.00 488 519 6.35
2018-02-14 13F-HR Williams Jones & Associates LLC 6,670 6,645 -0.37 679 623 -8.25
2017-11-13 13F-HR Marshall Wace North America L.P. 17,011 0 -100.00 1,310 0 -100.00
2018-02-14 13F-HR UBS Group AG Call 1,400 131
2018-02-13 13F-HR JP Morgan Chase & Co 29,929 26,718 -10.73 3,072 2,505 -18.46
2018-02-15 SC 13G/A VAN HERK INVESTMENTS B.V. 3,943,150 4,457,147 13.04
2018-02-12 13F-HR Advisors Preferred, LLC 1,029 0 -100.00 105 0 -100.00
2018-02-09 13F-HR PNC FINANCIAL SERVICES GROUP, INC. 60 6
2018-02-14 13F-HR BANK OF AMERICA CORP /DE/ 7,471 10,302 37.89 761 967 27.07
2018-02-09 13F-HR Bank of New York Mellon Corp 40,813 39,446 -3.35 4,152 3,698 -10.93
2018-01-19 13F-HR World Asset Management Inc 2,983 2,870 -3.79 304 269 -11.51
2018-02-15 13F-HR CASTLEARK MANAGEMENT LLC 9,875 6,770 -31.44 1,005 635 -36.82
2018-03-08 SC 13G/A GILEAD SCIENCES INC 6,760,701 6,760,701 0.00
2018-02-01 13F-HR VICTORY CAPITAL MANAGEMENT INC 18,296 1,715
2018-02-14 13F-HR SUSQUEHANNA INTERNATIONAL GROUP, LLP Call 2,000 0 -100.00 204 0 -100.00
2018-02-15 13F-HR JANE STREET GROUP, LLC 73,254 137,212 87.31 7,454 12,865 72.59
2018-02-14 13F-HR EcoR1 Capital, LLC 240,776 110,384 -54.15 24,499 10,350 -57.75
2018-02-09 13F-HR Unterberg Capital LLC 12,000 1,125
2018-01-10 13F-HR SIMPLEX TRADING, LLC 0 98 0 9
2017-11-13 13F-HR NORTHERN TRUST CORP 18,480 0 -100.00 1,414 0 -100.00
2018-02-14 13F-HR Tekla Capital Management LLC 19,000 53,200 180.00 1,933 4,988 158.04
2018-02-14 13F-HR Jefferies Group LLC 10,745 1,007
2018-02-14 13F-HR PERCEPTIVE ADVISORS LLC 206,405 206,305 -0.05 21,002 19,343 -7.90
2018-02-14 13F-HR DEUTSCHE BANK AG\ 78,622 72,120 -8.27 7,998 6,760 -15.48
2018-02-15 13F-HR Bb&t Investment Services, Inc. 186 18
2018-02-14 13F-HR BARCLAYS PLC 4,414 16 -99.64 449 2 -99.55
2018-02-14 13F-HR/A-1 BROOKSIDE CAPITAL MANAGEMENT LLC 42,026 0 -100.00 4,281 0 -100.00
2018-02-12 13F-HR FMR LLC / Fidelity 2,802,331 2,510,992 -10.40 285,137 235,431 -17.43
2018-02-16 13F-HR/A-1 OLD MISSION CAPITAL LLC 38,337 0 -100.00 3,901 0 -100.00
2018-01-30 13F-HR P.A.W. CAPITAL CORP 10,000 12,000 20.00 1,018 1,125 10.51
2018-02-14 13F-HR CLOUGH CAPITAL PARTNERS L P 72,453 66,453 -8.28 7,372 6,231 -15.48
2018-02-12 13F-HR COOKSON PEIRCE & CO INC 3,495 4,060 16.17 356 381 7.02
2018-02-13 13F-HR Renaissance Technologies LLC 266,500 235,200 -11.74 27,116 22,052 -18.68
2018-02-14 13F-HR PEAK6 Investments, L.P. Call 6,300 5,300 -15.87 641 497 -22.46
2018-02-13 13F-HR Wellington Management Group LLP 342,654 268,326 -21.69 34,865 25,158 -27.84
2018-02-14 13F-HR SUSQUEHANNA INTERNATIONAL GROUP, LLP Put 9,300 5,900 -36.56 946 553 -41.54
2018-02-07 13F-HR OPPENHEIMER ASSET MANAGEMENT INC. 53 0 -100.00 5 0 -100.00
2018-02-20 13F-HR/A-1 ALPS ADVISORS INC 50,045 56,310 12.52 5,092 5,280 3.69
2018-02-13 13F-HR GEODE CAPITAL MANAGEMENT, LLC 5,938 5,938 0.00 604 556 -7.95

Related Articles

RDHL: Redhill Biopharma Ltd (OTC:REDIF) Analysis and Research Report

2018-04-18 - Asif

History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...

SCYX: SCYNEXIS Analysis and Research Report

2018-04-16 - Asif

Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...

ENRT: Enertopia Corp (CNSX:TOP) Analysis and Research Report

2018-04-16 - Asif

Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...

FB: Facebook Analysis and Research Report

2018-04-15 - Asif

Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...

VSTM: Verastem Analysis and Research Report

2018-04-12 - Asif

Business Overview Verastem is a biopharmaceutical company focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients. The company's most advanced product candidates, duvelisib and defactinib, utilize a multi-faceted approach to treat cancers originating either in the blood or major organ systems. Verastem is currently evaluating these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer. The company believe that these compounds may be beneficial as therapeutics either as single agents or when used in combination with immuno-oncology agents or other current and emerging standard of care treatments in aggressive cancers that are poorly served by currently available therapies. Duvelisib targets the Phosphoinositide 3-kinase (PI3K) signaling pathway. The PI3K signaling pathway plays a centr...

CUSIP: 36315X101